MedTrace Logo

Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia

NCT03269292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-04-14

No results posted yet for this study

Summary

Autoimmune hemolytic anemia is characterized by shortened red blood cell survival and a positive Coombs test. The responsible autoantibodies may be either warm reactive or cold reactive. The rate of hemolysis and the severity of the anemia may vary from mild to severe and life-threatening. Diagnosis is made in the laboratory by the findings of anemia, reticulocytosis, a positive Coombs test, and specific serologic tests. The prognosis is generally good but renal failure and death sometimes occur, especially in cases mediated by drugs.

Conditions

  • Autoimmune Hemolytic Anemia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Essam Abdel Monem El-beih, professor · Assiut University

  • wael ahmed abbas, professor · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2021-01-24
Completion
2021-01-24

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269292 on ClinicalTrials.gov